Terumo : The Future of Terumo "Our vision and the path to it"

The Future of Terumo

"Our vision and the path to it"

May 14, 2024

Hikaru Samejima

Chief Executive Officer

Terumo Corporation

Forward-Looking Statements and Use of Document

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition. Information about products (including products currently in development) which is included in this material is not intended to constitute an advertisement or medical advice.

©TERUMO CORPORATION	2 / 10

Terumo's mission and creation of corporate value

Contributing to Society through Healthcare

Create	Enhance
social value	corporate value

Solutions

Social Mission

©TERUMO CORPORATION	3 / 10

Changes in healthcare & society, and Terumo's transformation

Thus far

Going forward

Innovative and comprehensive solutions

to medical issues

Medical device

manufacturer

Unyielding strengths

Developing and manufacturing

the highest quality medical devices

Aiming to create new markets, value, and solutions

Innovation

©TERUMO CORPORATION	4 / 10

Novel growth we have already achieved

TRI's Representative Products

(Introducer Sheath Kit)

Approach from wrist

FY22

Global Share

60%

					MicroVention
			Vascutek		(US)
Cardiovascular		(UK)
Div. of 3M (US)
Development of TRI-related products

FY90FY00FY10

©TERUMO CORPORATION	5 / 10

Bolton (US)

Angio-Seal (US)

Sequent (US)

CaridianBCT (US)

M&A

FY20

Revenue and market capitalization

Revenue growth

Market capitalization (compared to competitors)

FY14Present

FY95

115BJPY

TBCT

FY22 C&V

TMCS 820BJPY

FY09

303BJPY

CAGR 7.4%

Competitors 3.0%

CAGR 8.1%

Competitors10.6%

+189.2%.

Ref: In-house Research

©TERUMO CORPORATION	6 / 10

Terumo's Approach

GS26	Leap
forward

Discontinuous growth

Continuous growth

©TERUMO CORPORATION	7 / 10

Financial soundness in support of M&A

FY22 Gross Leverage (Compared to competitors)

Competitor median

Terumo

Ref: In-house Research

©TERUMO CORPORATION	8 / 10

Improve earning power; enhance corporate value

Enhance corporate value

FY22 Operating profit ratio (Compared to competitors)

Improve

cash acquisition capabilities

Sales Growth

Profit ratio

Capital efficiency

Competitor average	Terumo

Ref: In-house Research

©TERUMO CORPORATION	9 / 10

Terumo's goals and creation of corporate value

Contributing to Society through Healthcare

Create	Enhance
social value	corporate value

Solutions

Quality and safety	Stable supply of	Human resource	Promoting DE&I
products	development

Social Mission

©TERUMO CORPORATION	10 / 10